Analgesia through FKBP51 inhibition at disease onset confers lasting relief from sensory and emotional chronic pain symptoms
Sara Hestehave, Roxana Florea, Samuel Singleton, Alex J. H. Fedorec, Sara Caxaria, Oakley B. Morgan, Katharina Tatjana Kopp, Laurence A. Brown, Tim Heymann, Shafaq Sikandar, Felix Hausch, Stuart N. Peirson, Sandrine M. Géranton
This study shows that inhibiting FKBP51 early in joint pain reduces both sensory and emotional symptoms for up to 6 months, while late inhibition only provides temporary relief.
Proceedings of the National Academy of Sciences · Oct 30, 2025Peer-reviewedNeuroscience